US EditionEli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand
5 Articles
5 Articles
The pharmaceutical company Eli Lilly is in the spotlight with its Mounjaro drug, which has had a "positive" response in the Indian market since its introduction in March 2025. According to the original report, Mounjaro has managed to position itself firmly as a key player in the fight against diabetes and weight control in India, a country where these conditions are on the rise.Explosive sales and rising demandFrom its entry to the market, Mounj…
Eli Lilly says India response to obesity drug Mounjaro is ‘positive’, will focus on meeting demand - Regional Media News
By Rishika Sadam (Reuters) -Eli Lilly said the response for its blockbuster drug Mounjaro has been “positive” in India, adding that it is focusing on meeting demand for the drug in the world’s most populous country. The U.S.-based Lilly beat rival Novo Nordisk in March this year to introduce its diabetes and weight-loss drug in India, which is grappling with an increasing disease burden among its population of 1.4 billion. Mounjaro has sold more…
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
To view factuality data please Upgrade to Premium
